Fosun Pharma Gains NMPA Approval for Phase I Trial of XS-03 in Advanced Solid Tumors
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a leading healthcare conglomerate in China, has...
Drug
Cutia Therapeutics’ CU-20401 Completes Phase I Study for Obesity Treatment
China-based dermatology specialist Cutia Therapeutics (HKG: 2487) has announced the last subject out (LSO) in...
China Grand Pharma Initiates Phase III Trial for GPN00833 in Cataract Surgery Recovery
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced a significant milestone...
Sihuan Pharmaceutical Gains NMPA Approval for Innovative Type 2 Diabetes Treatment
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that it has received clinical...
Jiangsu Aidea’s HIV-1 Drug ACC017 Accepted for NMPA Review in China
China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that the National Medical Products...
Shandong Luoxin’s LX-039 Demonstrates Promise in Phase I Oncology Study at ESMO
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a China-based pharmaceutical innovator, has published...
Kintor’s Proxalutamide Shows Promise in Metastatic Breast Cancer Study at ESMO
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has published the latest data from a Phase Ic...
Walvax Biotechnology Secures BPOM Approval for Weuphoria Pneumococcal Vaccine
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced that it has received market approval...
Ascentage Pharma’s Pelcitoclax Shows Promise in ESMO Study for NSCLC
Suzhou-based pharmaceutical company Ascentage Pharma (HKG: 6855) has published the latest results from a Phase...
Changchun BCHT Biotechnology Invests in Influenza Vaccine Production Expansion
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced plans to invest RMB 805...
Yiling Pharmaceutical Gains NMPA Approval for XY0206 in AML Trial
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial...
Chengdu Kanghong Receives FDA Nod for Clinical Trial of Novel Depression Therapy KH607
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced that it has received...
Transcenta Holdings Unveils Updated Osemitamab Data in Advanced Gastric Cancer at ESMO
China-based biotech Transcenta Holdings Ltd (HKG: 6628) has presented updated efficacy data from the expansion...
Vcanbio Receives NMPA Approval for Clinical Study of VUM02 in SR-aGvHD Treatment
China-based biotechnology firm Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that...
Alphamab Oncology Presents Promising Data for KN046 and KN026 at ESMO 2023
China-based Alphamab Oncology (HKG: 9966) has released data snapshots from clinical studies for two of...
Janssen’s TAR-200 Shows High Complete Response Rate in Bladder Cancer Study
Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has published data from a Phase IIb...
Novartis’ Kisqali Plus Endocrine Therapy Shows Improved Survival in Early Breast Cancer Study
Switzerland-based pharmaceutical company Novartis (NYSE: NVS) has announced additional results from an ongoing Phase III...
Pfizer’s Penbraya Receives FDA Approval for Meningococcal Immunization
Pfizer Inc. (NYSE: PFE) announced last week that it has successfully registered its pentavalent meningococcal...
Health Canada Approves Pfizer and Sumitomo Pharma’s Myfembree for Endometriosis Pain Management
Health Canada has granted regulatory approval to Pfizer (NYSE: PFE) and Sumitomo Pharma (TYO: 4506)...
Shanghai Fudan-Zhangjiang’s ADC FZ-AD005 Accepted for NMPA Review in Advanced Solid Tumors
China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505) has announced that the National...